Profile data is unavailable for this security.
About the company
Beta Drugs Limited is an India-based company, which is engaged in manufacturing of the wide range of anti-cancer drugs in India. The Company operates through manufacturing of Oncology medicines segment. The Company offers a portfolio consisting of approximately 50 products catering to various oncology diseases, including breast, lung, head, and neck, colorectal, ovarian, gastric, brain, testicular renal, prostate, leukemia, lymphoma, myeloma, supportive. The Company’s oncology portfolio includes various brands, such as AB-PACLI, ADBIRON, ADCARB, ADCIST, Adlante, ADLEAP, ADMIDE, ADOXI, CAPAD, ARBAZ, FISTENT, BUSFAN, Triodelta and others. The Company's subsidiaries include Adley Lab Limited, Adley Formulations Private Limited.
- Revenue in INR (TTM)2.56bn
- Net income in INR347.57m
- Incorporated2005
- Employees315.00
- LocationBeta Drugs LtdSco 184, Sector 5, PanchkulaPANCHKULA 134114IndiaIND
- Phone+91 17 225854813
- Websitehttps://betadrugslimited.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jagsonpal Pharmaceuticals Ltd | 2.21bn | 245.16m | 9.68bn | 940.00 | 39.39 | -- | 36.86 | 4.39 | 9.30 | 9.30 | 83.51 | -- | -- | -- | -- | 2,347,522.00 | -- | 10.02 | -- | 12.51 | 54.09 | 58.47 | 11.11 | 8.03 | -- | 30.39 | -- | 36.24 | 8.79 | 13.33 | 41.72 | -- | -39.20 | 118.67 |
| Remus Pharmaceuticals Ltd | 450.27m | 85.03m | 11.42bn | 38.00 | 121.28 | 43.95 | 127.15 | 25.36 | 63.92 | 63.92 | 361.02 | 176.36 | -- | -- | -- | 11,849,290.00 | -- | -- | -- | -- | 52.39 | -- | 18.88 | -- | 1.35 | -- | 0.2933 | -- | 82.17 | -- | 151.14 | -- | -- | -- |
| Windlas Biotech Ltd | 6.00bn | 526.38m | 11.45bn | 1.05k | 21.87 | -- | 17.32 | 1.91 | 25.18 | 25.18 | 286.98 | -- | -- | -- | -- | 5,723,394.00 | -- | -- | -- | -- | 37.06 | -- | 8.77 | -- | -- | 59.55 | -- | -- | 10.12 | -- | 11.91 | -- | -- | -- |
| Vimta Labs Ltd | 3.20bn | 413.41m | 11.80bn | 1.37k | 28.98 | -- | 15.64 | 3.68 | 18.37 | 18.37 | 142.48 | -- | -- | -- | -- | 2,342,054.00 | -- | 10.50 | -- | 12.94 | 75.80 | 72.82 | 12.90 | 11.92 | -- | 28.50 | -- | 12.37 | 14.34 | 11.64 | 16.55 | 24.00 | 15.39 | 0.00 |
| Lincoln Pharmaceuticals Ltd | 5.51bn | 872.70m | 11.90bn | 1.70k | 13.64 | -- | 12.19 | 2.16 | 43.57 | 43.57 | 274.88 | -- | -- | -- | -- | 3,238,331.00 | -- | 13.75 | -- | 16.82 | 54.00 | 50.74 | 15.85 | 14.11 | -- | 41.54 | -- | 3.94 | 8.09 | 7.13 | 5.11 | 16.06 | 7.60 | 0.00 |
| Kopran Ltd | 5.79bn | 403.74m | 12.21bn | 394.00 | 30.45 | -- | 23.08 | 2.11 | 8.32 | 8.32 | 119.70 | -- | -- | -- | -- | 14,693,070.00 | -- | 8.64 | -- | 12.88 | 35.60 | 34.36 | 6.97 | 8.71 | -- | 36.80 | -- | -- | 15.38 | 11.85 | -55.38 | 5.86 | 39.08 | -- |
| Zota Health Care Ltd | 1.68bn | -100.65m | 12.88bn | 338.00 | -- | -- | 181.50 | 7.68 | -3.95 | -3.95 | 65.73 | -- | -- | -- | -- | 4,961,589.00 | -- | 2.13 | -- | 2.78 | 43.59 | 32.39 | -6.00 | 2.01 | -- | -1.81 | -- | 115.52 | 6.68 | 12.45 | -164.81 | -- | 56.84 | -14.14 |
| Syncom Formulations (India) Ltd | 2.50bn | 263.83m | 13.16bn | 799.00 | 41.18 | -- | 42.48 | 5.27 | 0.34 | 0.34 | 3.26 | -- | -- | -- | -- | 3,126,329.00 | -- | 7.69 | -- | 10.30 | 39.33 | 31.92 | 10.56 | 8.73 | -- | 4.72 | -- | -- | 2.09 | 7.17 | 1.42 | 18.34 | 25.48 | -- |
| Beta Drugs Ltd | 2.56bn | 347.57m | 13.29bn | 315.00 | 38.23 | 9.36 | 29.03 | 5.19 | 36.15 | 36.15 | 266.28 | 147.68 | 1.24 | 4.44 | 3.72 | 8,126,721.00 | 16.85 | -- | 25.36 | -- | 41.88 | -- | 13.58 | -- | 1.43 | 18.21 | 0.098 | -- | 23.54 | -- | 23.73 | -- | -- | -- |
| Bliss GVS Pharma Ltd | 7.57bn | 879.46m | 13.55bn | 763.00 | 15.63 | -- | 11.84 | 1.79 | 8.28 | 8.28 | 71.43 | -- | -- | -- | -- | 9,919,995.00 | -- | 7.72 | -- | 10.13 | 47.73 | 38.59 | 11.88 | 10.80 | -- | 10.26 | -- | 8.26 | 0.553 | 15.07 | 371.13 | 107.42 | 27.16 | -12.94 |
| Hester Biosciences Ltd | 2.93bn | 184.70m | 14.43bn | 693.00 | 75.28 | -- | 36.75 | 4.93 | 22.54 | 22.54 | 352.21 | -- | -- | -- | -- | 4,222,078.00 | -- | 8.22 | -- | 10.27 | 67.10 | 69.31 | 7.00 | 16.15 | -- | 2.15 | -- | 22.67 | 13.23 | 14.30 | -32.28 | 0.7733 | 27.62 | -4.36 |
| Ngl Fine Chem Ltd | 3.17bn | 380.04m | 16.32bn | 343.00 | 42.93 | -- | 32.81 | 5.15 | 61.52 | 61.52 | 513.13 | -- | -- | -- | -- | 9,241,813.00 | -- | 15.74 | -- | 20.73 | 53.94 | 45.27 | 11.99 | 13.43 | -- | 34.92 | -- | 3.47 | -12.42 | 19.17 | -58.92 | 10.23 | 5.65 | -- |
| SMS Pharmaceuticals Ltd | 6.13bn | 360.58m | 17.42bn | 1.10k | 48.27 | -- | 24.08 | 2.84 | 4.26 | 4.26 | 72.40 | -- | -- | -- | -- | 5,597,176.00 | -- | 5.86 | -- | 7.77 | 31.67 | 33.18 | 6.65 | 8.34 | -- | 3.13 | -- | 6.26 | 0.4188 | 2.35 | -111.35 | -- | 28.46 | 3.71 |
Data as of May 03 2024. Currency figures normalised to Beta Drugs Ltd's reporting currency: Indian Rupee INR
